Published in PLoS One on October 17, 2011
Identification of novel autoantibodies for detection of malignant mesothelioma. PLoS One (2013) 0.77
Advances in malignant mesothelioma. N Engl J Med (2005) 8.50
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Malignant mesothelioma. Lancet (2005) 3.93
Mesothelin-family proteins and diagnosis of mesothelioma. Lancet (2003) 2.98
Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev (2008) 2.30
The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res (2002) 2.24
Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity (2005) 2.08
The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol (2003) 1.96
Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol (2000) 1.62
Clinical validation of an autoantibody test for lung cancer. Ann Oncol (2010) 1.55
Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem (2010) 1.49
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res (2007) 1.45
Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis (2005) 1.44
The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis (2004) 1.31
The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta (2010) 1.22
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest (2007) 1.20
Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int J Colorectal Dis (2008) 1.16
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol (2008) 1.15
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med (2010) 1.14
Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol (2007) 1.12
Cell surface F1Fo ATP synthase: a new paradigm? Ann Med (2006) 1.11
Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev (2010) 1.10
Autoantibodies in rheumatoid arthritis: a review. Biomed Pharmacother (2006) 1.10
Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer (1991) 1.02
Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res (2008) 1.01
Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res (2010) 1.01
Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res (2004) 0.97
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem (2009) 0.97
Ecto-F1-ATPase and MHC-class I close association on cell membranes. Mol Immunol (2007) 0.94
Proteome analysis of Helicobacter pylori: major proteins of type strain NCTC 11637. Pathology (2001) 0.90
A message emerging from development: the repression of mitochondrial beta-F1-ATPase expression in cancer. J Bioenerg Biomembr (2007) 0.90
Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer (1998) 0.90
Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer's disease. Neurobiol Aging (2010) 0.87
Analysis of autoantibody epitopes on human thyroid peroxidase. Autoimmunity (1999) 0.83
Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer (2008) 0.82
p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer (2001) 0.79
Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med (2006) 4.09
Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer (2005) 3.31
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol (2003) 2.81
Cross-priming in health and disease. Nat Rev Immunol (2010) 2.51
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res (2003) 2.50
Mitochondrial dysfunction in autism. JAMA (2010) 2.04
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax (2007) 1.91
Characterization of activities of daily living in individuals with mild cognitive impairment. Am J Geriatr Psychiatry (2008) 1.86
Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res (2002) 1.66
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol (2003) 1.62
Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J (2010) 1.58
Protein consumption is an important predictor of lower limb bone mass in elderly women. Am J Clin Nutr (2005) 1.52
Prevalence of lower extremity pain and its association with functionality and quality of life in elderly women in Australia. J Rheumatol (2003) 1.42
Cognitive correlates of HVOT performance differ between individuals with mild cognitive impairment and normal controls. Arch Clin Neuropsychol (2006) 1.26
Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res (2010) 1.25
Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med (2008) 1.25
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One (2009) 1.24
Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Hum Mol Genet (2011) 1.23
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol (2002) 1.21
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest (2007) 1.20
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol (2008) 1.19
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother (2008) 1.18
Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol (2009) 1.17
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol (2008) 1.15
The MARS feasibility trial: conclusions not supported by data. Lancet Oncol (2011) 1.13
Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev (2006) 1.12
Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. J Clin Endocrinol Metab (2007) 1.12
ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol (2006) 1.11
A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res (2006) 1.11
Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev (2010) 1.10
Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res (2006) 1.09
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One (2013) 1.08
Tea drinking is associated with benefits on bone density in older women. Am J Clin Nutr (2007) 1.05
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res (2005) 1.02
Sustained activation of Akt elicits mitochondrial dysfunction to block Plasmodium falciparum infection in the mosquito host. PLoS Pathog (2013) 1.01
Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol (2004) 1.01
Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine (Phila Pa 1976) (2007) 1.01
The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol (2012) 1.01
Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS One (2012) 1.00
Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med (2009) 1.00
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best? Lung Cancer (2011) 0.98
Geriatric performance on an abbreviated version of the Boston naming test. Appl Neuropsychol (2007) 0.97
Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol (2008) 0.97
Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol (2010) 0.97
A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res (2006) 0.96
Evidence of reactive oxygen species-mediated damage to mitochondrial DNA in children with typical autism. Mol Autism (2013) 0.95
Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis. Am J Hum Genet (2008) 0.94
Physical activity and calcium consumption are important determinants of lower limb bone mass in older women. J Bone Miner Res (2004) 0.94
Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol (2012) 0.94
Toxicity of the flame-retardant BDE-49 on brain mitochondria and neuronal progenitor striatal cells enhanced by a PTEN-deficient background. Toxicol Sci (2013) 0.94
Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntington's disease. Hum Mol Genet (2012) 0.93
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol (2009) 0.92
Effects of vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women. Am J Clin Nutr (2002) 0.92
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol (2012) 0.89
Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers (2013) 0.88
CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol (2010) 0.88
Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity. Oncoimmunology (2012) 0.87
IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. Int Immunol (2012) 0.87
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening. Lung Cancer (2011) 0.87
Soluble mesothelin related protein in mesothelioma. J Thorac Oncol (2006) 0.86
Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. Oncoimmunology (2012) 0.85
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol (2014) 0.85
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am (2005) 0.85
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Curr Opin Pulm Med (2015) 0.84
Combining immunotherapy with chemotherapy to treat cancer. Discov Med (2005) 0.84
Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. J Immunother (2013) 0.83
Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer (2013) 0.82
Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. J Transl Med (2014) 0.82
Effects of a herbal extract on the bone density, strength and markers of bone turnover of mature ovariectomized rats. Am J Chin Med (2003) 0.82
CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells. Immunol Cell Biol (2004) 0.81
Clinical evaluation and biochemical analyses of thiamine deficiency in Pacific harbor seals (Phoca vitulina) maintained at a zoological facility. J Am Vet Med Assoc (2013) 0.81
Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother (2012) 0.81
Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. Cancer Immunol Immunother (2005) 0.81
Common sequence variation in FLNB regulates bone structure in women in the general population and FLNB mRNA expression in osteoblasts in vitro. J Bone Miner Res (2009) 0.80
Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? Lung Cancer (2013) 0.78
Scientists appeal to Quebec Premier Charest to stop exporting asbestos to the developing world. Int J Occup Environ Health (2010) 0.77
Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. J Immunother (2005) 0.77
Gene therapy of mesothelioma. Expert Opin Biol Ther (2005) 0.76
Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure. CNS Neurol Disord Drug Targets (2016) 0.76
A new mutation in GJC2 associated with subclinical leukodystrophy. J Neurol (2014) 0.76
The importance of calculating absolute rather than relative fracture risk. Bone (2007) 0.75
Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Ther (2003) 0.75
Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol (2010) 0.75
Current chemotherapeutic treatment of malignant pleural mesothelioma. Expert Opin Pharmacother (2004) 0.75
Chocolate consumption and bone density in older women. Am J Clin Nutr (2008) 0.75